Search research articles

ABOUT JoVE

Overview Leadership Blog JoVE Help Center

AUTHORS

Publishing Process Editorial Board Scope & Policies Peer Review FAQ Submit

LIBRARIANS

Testimonials Subscriptions Access Resources Library Advisory Board FAQ

RESEARCH

JoVE Journal Methods Collections JoVE Encyclopedia of Experiments Archive

EDUCATION

JoVE Core JoVE Business JoVE Science Education JoVE Lab Manual Faculty Resource Center Faculty Site

Terms & Conditions of Use

Search research articles

Related Experiment Video

Updated: May 28, 2026

Primary Sjogren's Syndrome Associated with Lung Adenocarcinoma: Probing the Potential Common Pathogenic Mechanisms and Experimental Verification

Primary Sjogren's Syndrome Associated with Lung Adenocarcinoma: Probing the Potential Common Pathogenic Mechanisms and Experimental Verification

Published on: September 20, 2024

Integrative Multi-Omics Analysis Identifies IL18R1 as a Circulating Prognostic Biomarker for Risk Stratification in

Shengjuan Hu¹, Sicong Li², Yiyuan Cui²

¹Department of Hematology and Oncology, Dongzhimen Hospital, Beijing University of Chinese Medicine, Beijing 100700, China.

|May 27, 2026

Summary

Related Concept Videos

Non-LTR Retrotransposons

Non-LTR Retrotransposons

As the name suggests, non-LTR retrotransposons lack the long terminal repeats characteristic of the LTR retrotransposons. Additionally, both LTR and non-LTR retrotransposons use distinct mechanisms of mobilization. Non-LTR retrotransposons are further divided into two classes - Long interspersed nuclear elements (LINEs) and short interspersed nuclear elements (SINEs), both of which occur abundantly in most mammals, including humans. Some of the active non-LTR retrotransposons in humans are L1...

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by

Same author

Physicians' Knowledge, Attitude, and Experience of Pharmacogenomic Testing in China.

Journal of personalized medicine·2022

Same author

Clinical Pharmacists' Knowledge of and Attitudes toward Pharmacogenomic Testing in China.

Journal of personalized medicine·2022

Same author

Research Progress on Natural Products' Therapeutic Effects on Atrial Fibrillation by Regulating Ion Channels.

Cardiovascular therapeutics·2022

Same author

Research Progress on Natural Product Ingredients' Therapeutic Effects on Parkinson's Disease by Regulating Autophagy.

Evidence-based complementary and alternative medicine : eCAM·2021

Same author

Research Progress on Anti-Inflammatory Effects and Mechanisms of Alkaloids from Chinese Medical Herbs.

Evidence-based complementary and alternative medicine : eCAM·2020

Same author

Research Progress of Male Reproductive Toxicity of Chinese Materia Medicas.

Evidence-based complementary and alternative medicine : eCAM·2019

Same journal

RETRACTED: Sabir et al. DNA Based and Stimuli-Responsive Smart Nanocarrier for Diagnosis and Treatment of Cancer: Applications and Challenges. <i>Cancers</i> 2021, <i>13</i>, 3396.

Cancers·2026

Same journal

Correction: Adeluola et al. Chemoprevention of 4-NQO-Induced Oral Cancer by the Combination of Resveratrol and EGCG: In Vivo, In Silico and In Vitro Studies. <i>Cancers</i> 2026, <i>18</i>, 1098.

Cancers·2026

Same journal

Correction: Peñalver et al. Guidelines for Diagnosis, Treatment, and Follow-Up of Patients with Follicular Lymphoma-Spanish Lymphoma Group (GELTAMO) 2026. <i>Cancers</i> 2026, <i>18</i>, 395.

Cancers·2026

Same journal

Correction: Accorsi Buttini et al. Development of a Simplified Geriatric Score-4 (SGS-4) to Predict Outcomes After Allogeneic Hematopoietic Stem Cell Transplantation in Patients Aged over 50. <i>Cancers</i> 2025, <i>17</i>, 3278.

Cancers·2026

Same journal

Age-Stratified Long-Term Outcomes of Immune Checkpoint Inhibitors for Stage IV Melanoma and NSCLC in The Netherlands: A Population-Based Study.

Cancers·2026

Same journal

Targeting Ferroptosis in Glioblastoma: Molecular Mechanisms, Tumor Microenvironment, and Therapeutic Opportunities.

Cancers·2026

See all related articles

This summary is machine-generated.

This study identifies ACE, AGER, and IL18R1 as protective factors against small cell lung cancer (SCLC) progression. Plasma IL18R1 combined with clinical data offers a new prognostic tool for extensive-stage SCLC patients.

Area of Science:

Oncology
Genomics
Biomarker Discovery

Background:

Small cell lung cancer (SCLC) has a poor prognosis and lacks effective biomarkers for risk stratification.
Identifying circulating prognostic biomarkers is crucial for improving patient outcomes.
This study focuses on discovering novel biomarkers for SCLC risk stratification.

Purpose of the Study:

To identify circulating prognostic biomarkers for small cell lung cancer (SCLC).
To develop a diagnostic and prognostic model using machine learning and multi-omics data.
To validate the prognostic utility of the identified biomarker IL18R1 in a prospective cohort.

Main Methods:

Integrative multi-omics analysis (pQTL/eQTL, differential expression, WGCNA) to prioritize SCLC risk-associated genes.

Keywords:

IL18R1 biomarker machine learning single-cell analysis small cell lung cancer

Related Experiment Videos

Last Updated: May 28, 2026

Primary Sjogren's Syndrome Associated with Lung Adenocarcinoma: Probing the Potential Common Pathogenic Mechanisms and Experimental Verification

Primary Sjogren's Syndrome Associated with Lung Adenocarcinoma: Probing the Potential Common Pathogenic Mechanisms and Experimental Verification

Published on: September 20, 2024

Machine learning approaches (Elastic Net, LASSO-Cox) to develop diagnostic and prognostic models.

Single-cell transcriptomics and prospective clinical cohort validation of IL18R1 as a prognostic biomarker.

Main Results:

ACE, AGER, and IL18R1 were identified as SCLC-protective genes.
A two-gene signature (AGER, IL18R1) demonstrated robust diagnostic accuracy.
Lower plasma IL18R1 levels independently predicted shorter progression-free survival (PFS) in extensive-stage SCLC patients.
A prognostic model integrating plasma IL18R1 and clinical parameters stratified patients into distinct risk groups.

Conclusions:

ACE, AGER, and IL18R1 are protective factors against SCLC progression.
Plasma IL18R1 is a promising prognostic biomarker for extensive-stage SCLC.
Integrating plasma IL18R1 with clinical variables provides a valuable prognostic tool for extensive-stage SCLC.